Pharma Stocks

AbbVie Earnings: Skyrizi and Rinvoq Now Drive the Post-Humira Mix

by
AbbVie earnings Q2 2026 showing Skyrizi and Rinvoq replacing Humira revenue

AbbVie earnings for Q2 2026 make the company’s post-Humira transition much easier to quantify. Revenue reached $16.990 billion, up 10.2% year over year on a reported basis, but the more revealing change is inside the product mix. Skyrizi generated $5.505 billion of quarterly revenue and Rinvoq produced $2.525 billion. Together, those two products accounted for … Read more

Patent Cliff Risk: Essential Guide to Pharma Revenue Exposure

by
Patent cliff risk analysis for pharma stocks using revenue exposure, competition timing, and replacement sales

Patent cliff risk is best analyzed as a revenue-replacement problem, not as a single patent-expiration date. For a pharmaceutical investor, the useful questions are how much revenue is concentrated in the protected product, when meaningful generic or biosimilar competition can actually begin, how quickly that revenue may erode, and whether other products can fill the … Read more